Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.

11 Dec 2020

Destiny Pharma - CEO Interview - December 2020

Neil updates on exceptionally busy recent months for infection prevention experts Destiny:

- portfolio transformed with addition of M3, a Phase 3-ready biotherapeutic product for the prevention of C. difficile infection

- first lead product XF-73 on track to end Phase 2b trial soon, with its results in Q1 2021

- agreement with SporeGen on the preventative therapy for COVID-19

- £10.4m raised by equity placing

If trial is positive, Destiny Pharma will be well-funded with two Phase 3-ready products

Download as a PDF file

Return to Destiny Pharma

Register to be first

Get research on the companies that interest you straight to your inbox

Equity Development is a partner to successful companies looking to enhance their investor relations. Our top-rated analysts produce best in class investment research. Based in London, UK, we help our clients connect with investors via presentations and interviews.

Equity Development Limited 3rd Floor, 80 Cheapside, London, EC2V 6EE

Website design & development by Breckenridge